Supplementary Figure S2 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Supplementary Figure S2. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with first-line osimertinib. The point estimate for median progression free survival associated with each mutation is listed to the right of the figure legend.</p

Supplementary Figure S3 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutation is listed to the right of the figure legend.</p

Supplementary Table S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Supplementary Table S1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented ≤2.5% of the study cohort. Patients with + for “Smoking History” are those with either a prior or current smoking history. PFS=Progression free survival; OS= Overall survival; à denotes patients who have not yet experienced an event for a time to event endpoint.</p

Supplementary Figure S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Supplementary Figure S1. Multi-institution cohort of patients with tumors harboring EGFR Exon 19 deletions. Primary analyses were performed on patients with tumors harboring E746_A750del and L747_A750>P, while investigation into additional uncommon variants was descriptive only. Patient numbers do not reflect the true prevalence of each variant since this cohort is selectively enriched for uncommon exon 19 deletions.</p